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orafenib, an oral multikinase inhibitor, is
approved by the US Food and Drug Adminis-
tration for the treatment of patients with
unresectable hepatocellular carcinoma (HCC) and
advanced renal cell carcinoma (RCC).1 In phase III
studies, patients treated with single-agent sorafenib
showed a significant advantage for progression-free
survival (PFS) compared with placebo (in RCC) and
an overall survival benefit (in HCC).2–6 An overall
survival benefit was also observed in patients with
RCC when data were censored for placebo-assigned
patients who had crossed over to sorafenib treat-
ment.6 Promising results from phase II studies with
single-agent sorafenib in patients with iodine-
refractory differentiated thyroid cancer (DTC;
median PFS ¼ 79 weeks)7–10 prompted initiation of
the randomized, placebo-controlled, phase III DECI-
SION study, which reached completion in December
2012.11,12
Sorafenib is currently being evaluated in other
phase II and phase III clinical trials, which include
treatment as part of multimodality care (HCC) and in
combination with chemotherapeutic agents (meta-
static breast cancer).13
The recommended starting dose for sorafenib in
patients with HCC and RCC is 400 mg (two tablets)S1
M.S. Brose et alS2given orally twice a day, without food.1 In the
recently reported final analysis of GIDEON (Global
Investigation of Therapeutic Decisions in Hepatocel-
lular Carcinoma and of Its Treatment With Sorafe-
nib), a non-interventional phase IV study in patients
with HCC, data showed that the average daily dose
of sorafenib was slightly higher in patients with
Child-Pugh B (741.5 mg) than with Child-Pugh A
(677 mg), but overall, dosing was generally consis-
tent across patients regardless of Child-Pugh status.14
In the phase II and phase III DTC studies, the starting
dose is 400 mg, twice a day.7–10 However, treatment
interruptions and/or dose reductions may be war-
ranted to manage some adverse events (AEs). The
most common AEs related to sorafenib treatment
that may impact quality of life (QOL) include hand–
foot skin reaction (HFSR), rash (often occurring as a
papular, erythematous eruption that can involve
extremities, as well as the trunk), upper and lower
gastrointestinal (GI) distress, and fatigue1,15
(Tables 1 and 2).
Hypertension (HTN), another AE that is commonly
observed, does not directly affect QOL, while AEs that
are less common or are rare but of concern include
cardiovascular events (other than HTN, and including
congestive heart failure, myocardial ischemia and/or
infarction, hypertensive crisis, and QT prolongation),
portal HTN and variceal bleeding, wound healing, and
squamous cell carcinoma of the skin.1
Patients with visceral-organ (RCC and HCC) and
non–visceral-organ (DTC) disease may have different
challenges (eg, patients with HCC often have under-
lying cirrhosis, and patients with RCC may have HTN
and hypercalcemia, while patients with DTC may have
hypocalcemia). Furthermore, with declining health,
there is an increase in AEs overall,16,17 which may or
may not be directly related to treatment with sorafenib.
In contrast, patients with non–visceral-organ dis-
ease (ie, DTC) are relatively healthy and may be
treated long-term with sorafenib. Therefore, the
approach to management of AEs may vary by patient
population and by length of treatment. Regardless of
the patient population, however, the successful
management of AEs may allow patients to tolerate
the full dose of sorafenib, thereby enabling patients
to remain on the sorafenib treatment and maintain a
good QOL.
Data presented here include safety outcomes from
the pivotal phase III sorafenib (single-agent) studies
that supported its approval by the US Food and Drug
Administration for use in patients with HCC and
RCC. This article also includes outcomes from the
phase II DTC (single-agent) trial, which has been
completed and published, met its primary end point,
and led to the phase III study. Recommendations for
the management of common AEs in patients taking
sorafenib are provided per the clinical experience ofthe authors, as well as per further guidance from the
literature.SORAFENIB-RELATED AEs
Hand–Foot Skin Reaction
HFSRs, which are usually Common Terminology
Criteria for Adverse Events (CTCAE) grade 1 or 2
(see Table 3), can have a significant effect on patient
QOL. HFSRs generally appear within the first 6 weeks
of sorafenib treatment1 but may occur as early as 1–2
weeks following treatment initiation.1,18
Management Approach
The main goal for the management of HFSR is to
allow patients to maintain their sorafenib dose for as
long as is indicated. This may be accomplished
through patient education and proactive manage-
ment, which often include keeping hands and feet
moisturized with a thick urea-based cream,19 remov-
ing thick calluses (hyperkeratosis), wearing comfort-
able shoes with minimal pressure points, and
avoiding hot water18,20–24 (see Table 3). The corner-
stone of management is to keep skin well hydrated,
remove calluses regularly, and use pain medication
as needed.
Based on the clinical experience of the authors, it
is highly recommended that clinicians see patients in
2-week intervals for the first 2 months following
sorafenib initiation to proactively manage HFSR.
With grade 1 or 2 HFSR, patients generally can
continue sorafenib treatment without any changes
to dose or administration.1 Intolerable grade 2 HFSR
that does not improve following one or two dose
holidays or a grade 3 episode (eg, patient unable to
walk) may require dose reduction.25 HFSR does not
tend to worsen after 3 months of sorafenib treat-
ment. In a subgroup analysis of the phase III
TARGET (Treatment Approaches in Renal Cancer
Global Evaluation Trial) trial in patients with RCC,
the overall incidence of HFSR tended to peak after
the first cycle (29%), with fewer cases reported
subsequently (16%, 3%, and 1%, during cycles 2, 3,
and 4, respectively). Grade 3/4 HFSR, when it did
occur, also developed most frequently in early cycles
(cycles 1‒5 and 7).26 In a phase II trial of patients
with DTC who were treated with sorafenib (N ¼
55), HFSR severity peaked at treatment cycle 2 and
declined by cycle 6 (39% and 10% of patients had
grade 2–3 HFSR in cycles 2 and 6, respectively); 17
patients (31%) required dose reduction due to
HSFR.27 With proper management, beginning at
the earliest signs of HFSR, patients may be guided
over the toughest period and continue therapy,
without sorafenib dose reductions or interruptions
in therapy.28
Table 1. Incidence of Adverse Events and Laboratory Abnormalities in Patients With Visceral-Organ Disease, by CTCAE Grade 3 in the
Pivotal Phase III Studies*
HCC†,1,2 RCC‡,1,6
Sorafenib (n ¼ 297) Placebo (n ¼ 302) Sorafenib (n ¼ 452) Placebo (n ¼ 451)
Crossover From Placebo
to Sorafenib (n ¼ 216)
Parameter, % Any Grade Grades 3/4 Any Grade Grades 3/4 Any Grade Grades 3/4 Any Grade Grades 3/4 Any Grade Grades 3/4
Adverse events
Dermatologic
HFSR 21 8 3 o1 33 6 8 o1 37 7
Rash/desquamation 19 1 14 0 31 0 4 0 34 0
Alopecia 14 0 2 0 31 0 4 0 34 0
Gastrointestinal
Diarrhea 55 10 25 2 48 3 11 1 48 5
Nausea 24 1 20 3 19 o1 12 o1 14 1
Vomiting 15 2 11 2 12 1 6 o1 9 1
Anorexia 229 3 18 3 14 o1 7 1 16 1
Constipation 14 0 10 0 7 0 4 0 7 0
Constitutional
Fatigue 46 10 45 14 29 3 16 1 25 5
Weight loss 30 2 10 11 8 1 1 0 11 1
Cardiovascular
Hypertension 9 4 4 1 17 4 1 0 13 4
Laboratory abnormalities
Hypophosphatemia 35 11 11 3 NR NR NR NR NR NR
Hypocalcemia 27 2 15 1 NR NR NR NR NR NR
⁎ The pivotal phase III studies that led to approval of sorafenib by the US Food and Drug Administrator are included in this table;
† Includes patients in both the SHARP (N ¼ 599) and the Asia-Paciﬁc (N ¼ 224) clinical trials. The dosing and administration in both trials was oral sorafenib 400 mg or placebo, twice a
day, in 6-week cycles.
‡ In the TARGET trial, patients with RCC received continuous, twice-a-day treatment with either sorafenib 400 mg or placebo. After a planned analysis, 48% of patients from the placebo
group crossed over to sorafenib, after a progression-free survival advantage was demonstrated in the sorafenib group.
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; HCC, hepatocellular carcinoma; HFSR, hand–foot skin reaction; NR, data not reported; SHARP, Sorafenib HCC
Assessment Randomized Protocol; TARGET, Treatment Approaches in Renal Cancer Global Evaluation Trial.
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Table 2. Incidence of Adverse Effects and
Laboratory Abnormalities in Patients With
Non–Visceral-Organ Disease, by CTCAE Grade
3, in the Phase II DTC Study*
DTC†,10
Sorafenib (N ¼ 33)
Adverse Events, % Grades 1/2 Grades 3/4
Dermatologic
HFSR 83‡ 10‡
Rash/
desquamation
70 10
Alopecia 43 0
Gastrointestinal
Diarrhea 73 7
Nausea/vomiting 30 0
Anorexia 17 3
Constipation 7 0
Constitutional
Fatigue 60 3
Weight loss 50 10
Cardiovascular/
pulmonary
Hypertension 30 13
⁎ Only the phase II single-agent sorafenib study, which was
completed, met its primary end point, was published, and led to
a phase III study, is included in this table.
† Patients in the DTC phase II study received sorafenib 400 mg
orally twice a day;
‡ Palmar–plantar erythema.
Abbreviations: CTCAE, Common Terminology Criteria for
Adverse Events; DTC, radioactive iodine-refractory differen-
tiated thyroid cancer; HFSR, hand–foot skin reaction.
M.S. Brose et alS4Rash
Rash is common in patients treated with sorafe-
nib2,6,10 (see Tables 1 and 2) and presents as a
macular or papular rash over the extremities and
sometimes over the trunk, often occurring in the first
month of treatment.26 In the phase II sorafenib DTC
study, rash severity peaked at cycle 1 and declined
by cycle 3 (19% and 5% of patients had grade 2–3
rash in cycles 1 and 3, respectively).27 Overall, the
severity and prevalence of skin AEs (including rash
and HFSR) reached a steady state following cycle 12.
Of the 30 (55%) patients who required dose reduc-
tions because of skin AEs, 31% were able to resume
their full dose of sorafenib by the end of the study.Management Approach
Most rashes are not painful and resolve on their
own, and patient education is all that is required.
Rashes that cause discomfort may respond to a
change to mild, perfume-free soaps; increased emol-
lient applications; avoidance of hot water; and/or
wearing loose, natural fabric clothing.29 Publisheddata suggest that topical corticosteroids may have
some efficacy early in therapy when the rash is mild.
In addition, although antihistamines (eg, Benadryl
[McNeil-PPC, Inc., Fort Washington, PA]) may be
considered, they have shown minimal efficacy.30
Severe rash in four patients treated by the authors
was resolved by a short course of oral corticosteroids
(unpublished data); however, no clinical trial data
exist at this time to support the use of this approach.
Upper and Lower GI Distress
Epigastric Pain: Dyspepsia
Upper GI effects are often caused by reflux or
dyspepsia, and grade 1 or grade 2 dyspepsia symp-
toms commonly occur in patients treated with
sorafenib1,2,6,10 (see Tables 1 and 2). Epigastric pain,
which may affect patients over the long term, can
cause appetite loss and anorexia, which may lead to
(sometimes severe) weight loss.
Management Approach. Management of dyspepsia
(Table 4) is generally similar between tumor types and
may be controlled via a low-fiber diet, changes in the
timing of sorafenib dosing to always occur before ameal,
and the use of supplements, such as probiotics and
digestive enzymes. If these approaches are ineffective,
the addition of a proton pump inhibitor22 and sucralfate
(Carafate; Aptalis Pharma US, Bridgewater, NJ) sus-
pension, which is indicated for the treatment of peptic
ulcers37 and also has been shown to be effective in
patients with gastroesophageal reflux disease (GERD),38
may be helpful. However, recent recommendations
based on strength of evidence for the superiority of
proton pump inhibitors over sucralfate for GERD
management indicates that there may be little role for
sucralfate in the nonpregnant patient with GERD.39
Diarrhea
Diarrhea is often associated with sorafenib therapy
and is most commonly CTCAE grade 1/21,2,6,10 (see
Tables 1 and 2). Diarrhea may begin early in treatment
(immediately or up to 8 weeks) in patients with visceral-
organ disease. In the TARGET trial in patients with RCC,
diarrhea tended to develop early (within 1 month), and
the overall incidence of diarrhea rose during early cycles
of sorafenib treatment (23%, 23%, 29%, and 39% in
cycles 1, 2, 3, and 4, respectively).26 However, in
patients with DTC, diarrhea often occurs much later;
approximately 3–4 months after the initiation of sorafe-
nib treatment. In DTC, onset of diarrhea may be slow
and then remain constant, aggravated primarily by poor
dietary choices. The authors have observed that, regard-
less of tumor type (RCC, HCC, DTC), episodes of
diarrhea occur intermittently (eg, 2–3 days per week)
in the majority (80%) of patients; however, in HCC,
Table 3. Recommendations for the Prophylaxis and Management of HFSR
Timing Management Recommendations for HFSR Toxicity18–24
Prior to sorafenib treatment 1. Baseline physical for preexisting hyperkeratosis
2. Patient education (prevention and management)
3. Frequent (bid) emollients used on hands and feet to
maintain skin hydration
4. Manicure/pedicure to control calluses
5. Use a keratolytic agent on calluses bid to aid exfoliation
(20%–40% urea-based creams (eg, Carmol 40 [Doak
Dermatologics, Fairﬁeld, NJ] with Keralac [Doak
Dermatologics, Fairﬁeld, NJ])*
6. Protect pressure points and tender areas of feet with insole
cushions, shock-absorbing soles, soft/comfortable shoes
(eg, Crocs [Crocs Retail, Inc., Niwot, CO]), and so forth
Throughout sorafenib treatment, regardless
of HFSR toxicity grade (0–4)
Continue with #2–#6 above, plus…
7. Monitor patient weekly during the ﬁrst 6 weeks following
sorafenib treatment initiation
8. Avoid hot water
9. Wear thick cotton gloves and/or socks
10. Wear cotton gloves/socks at night after applying emollients
to prevent further injury and retain moisture
11. Foot soaks in cool water with magnesium sulfate to reduce
pain and soften calluses
During sorafenib treatment, by
CTCAE (v3) toxicity grade
Recommendations, Regardless of Tumor Type
First Approach Second Approach
HFSR grade 1
Mild: minimal skin changes or
dermatitis (eg, erythema)
without pain
Follow recommendations 2–11
above, plus…
● Possible topical therapy for
symptomatic relief
● Dose modiﬁcation not
recommended
● Two-week follow-up
HFSR grade 2
Moderate: skin changes (eg,
peeling, blisters, bleeding,
edema) or pain, not interfering
with function
● Follow “throughout
treatment” recommendations
above, plus…
● One-week follow-up
● Clobetasol 0.05% ointment,
bid, applied to
erythematous areas
● Topical analgesic (eg,
lidocaine 2%) for pain
● Dose modiﬁcation usually not
needed
● If dose modiﬁcation is
warranted, consider 50% dose
reduction (from 800 to 400 mg
qd) 7–28 days until the HFSR
reaches grade 1 or 0, and then
resume full dosing
● If not resolved, interrupt
treatment until HFSR resolved,
and then resume at a reduced
dose (400 mg qd)†
● Repeat steps 2 or 3 for second or
third occurrence
● Upon fourth occurrence,
discontinue sorafenib based on
clinical judgment and patient
preference
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Table 3 (continued)
During sorafenib treatment, by
CTCAE (v3) toxicity grade
Recommendations, Regardless of Tumor Type
First Approach Second Approach
HFSR grade 3
Severe: ulcerative dermatitis or
skin changes with pain that
interferes with function
Follow recommendations 2–11
above, plus…
● One-week follow-up
● Topical therapy for
symptomatic relief
(cortisone cream)
● Systemic strategies to reduce
symptoms, eg, pyridoxine
(50–150 mg/day), may be of
beneﬁt
● Dose modiﬁcation MAY be
warranted
● Interrupt treatment for ≥7 days
until HFSR reaches grade 1 or 0
● Resume treatment at 50% of full
dose (400 mg qd)
● Monitor patient for toxicity; if
none, escalate to full dose
● For second occurrence, reduce
dosage to 400 mg qd or once
every other day
● For third or fourth occurrence,
treatment may be resumed
based on clinical judgment or
patient preference
⁎ With frequent cream usage, there is an increased risk of tinea pedis (“athlete’s foot”), which should be distinguished from HFSR.
† To date, there is no evidence to support the relation of sorafenib drug interruptions with HFSR toxicity and clinical outcomes.
Abbreviations: bid, 2 times per day; CTCAE, Common Terminology Criteria for Adverse Events; DTC, radioactive iodine-refractory
differentiated thyroid cancer; HCC, hepatocellular carcinoma; HFSR, hand-foot skin reaction; NSAID, nonsteroidal anti-inﬂammatory
drug; qd, once per day; RCC, renal cell carcinoma.
M.S. Brose et alS6diarrhea may also occur more frequently (up to 10–20
times per day in approximately 5% of patients) (unpub-
lished author data). Concurrent use of the disaccharide
lactose for treatment of hepatic encephalopathy in
patients with HCC may provide another level of GI
distress, as it is commonly a source of diarrhea.40
Uncontrolled diarrhea has important implications for
dehydration and electrolyte imbalance,31,34 as well as
having an obvious impact on patients’ QOL31,35 and
their ability to tolerate their cancer treatment.
Management Approach. The treatment approach
for diarrhea (see Table 4) is similar across tumor types
and generally includes dietary adjustments,
symptomatic control of diarrhea, and monitoring/
managing electrolytes. In the experience of the
authors, the need to reduce or interrupt the
sorafenib dose for grade 1 or 2 events is rare. When
symptomatic treatment for diarrhea is needed, most
patients are able to obtain good control on a single
drug, such as loperamide, which can be increased until
control is achieved. However, for patients with HCC
who are taking lactulose, their dose may be decreased.
Fatigue
Fatigue was frequently reported in patients in the
sorafenib phase III (HCC and RCC) and phase II (DTC)
clinical studies2,6,10 (see Tables 1 and 2). Fatigue is
generally self-limited, commonly occurring in the first
4–6 months of sorafenib treatment and often resolvingafter approximately 5–6 months on treatment (author
experience). In patients with HCC, however, it is
often unclear whether the fatigue is drug-related or
due to the underlying liver disease or other cancer
treatment, such as recent or ongoing transcatheter
arterial chemoembolization procedures.41
Management Approach. Because fatigue may be
symptomatic of other underlying issues, patients should
be evaluated for other treatable contributing factors,
including emotional distress (ie, depression, anxiety),
adverse events of other medications, pain, anemia,
sleep disturbances, nutritional issues (ie, weight or
food intake changes, imbalances in fluids/electrolytes),
decreased physical activity, and comorbid conditions (ie,
alcohol/substance abuse; infection; cardiac, endocrine,
gastrointestinal, hepatic, neurologic, pulmonary, or renal
dysfunction).42 Medication is generally not needed for
patientswith fatigue.42UnlikeHFSR anddiarrhea, fatigue
associated with sorafenib is likely to resolve around
month 6 without treatment or dose adjustment.
Educating patients regarding what to expect and how
to adjust their schedules accordingly is usually the key to
managing symptoms of fatigue (Table 5).
Hypertension and Other Cardiovascular Issues
Hypertension
HTN has been reported to occur at a higher
incidence in patients with DTC10 than in patients
Table 4. Recommendations for the Management of Lower and Upper GI Distress
Management Recommendations for Diarrhea and Dyspepsia
Diarrhea1,31–36 Dyspepsia22,38
General Tumor-Speciﬁc General Tumor-Speciﬁc
General ● Treatment is often symptomatic
● Patient education and proactive
management is key
● Sorafenib dose reduction is
rarely needed for grade 1 or
grade 2 diarrhea
● Note that drugs may change
taste, which can affect
eating habits
● Chronic diarrhea can lead to
dehydration and electrolyte
imbalances
● HCC: remind patients to adjust
their lactulose as needed
● Dyspepsia can usually be
managed, and sorafenib dose
reduction is rarely required
● Epigastric pain, which may
affect patients over the long
term, affects appetite, which
can lead to (sometimes severe)
weight loss
Patient
education
● Prior to and throughout
sorafenib treatment, educate
patients regarding diarrhea
onset and management, as well
as dietary restrictions
● Prior to and throughout
sorafenib treatment, educate
patients as to dietary restrictions
Patient
monitoring
● Monitor/manage electrolytes in
patients who may be
dehydrated
● Patients should alert their
healthcare team regarding
changes in bowel habits
● Sharp pains in lower gut (ie,
cramping, abdominal pain) or
an inability to pass stool should
be evaluated for risk of GI
perforation (very rare),
particularly in patients with a
history of diverticulitis or
diverticulosis
● Patients should alert their
healthcare team regarding
onset of GI distress
A
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Table 4 (continued)
Management Recommendations for Diarrhea and Dyspepsia
Diarrhea1,31–36 Dyspepsia22,38
General Tumor-Speciﬁc General Tumor-Speciﬁc
● Assess for Clostridium difﬁcile
infection or spontaneous
peritonitis (not related to
sorafenib treatment)
Sorafenib dose
timing with
food/water
● Timing of sorafenib dosing with
food differs by tumor type
● RCC and
HCC: Take
sorafenib
dose with
bread or
crackers
● DTC: Take
sorafenib 30
minutes
(instead of
1 hour)
following a
meal
Diet ● Avoid caffeine, dairy, and greasy
foods (worsens GI distress)
● Adding or avoiding ﬁber is
dependent on tumor type
● Adverse foods can be patient-
speciﬁc: it is recommended that
patients keep food diaries
● HCC: adding ﬁber to the diet
(eg, Beneﬁber supplement
[Novartis Consumer Health,
Parsippay, NJ]) may be helpful
● DTC: a diet low in ﬁber is
recommended
● Follow recommendations for
diarrhea
● Minimize intake of gas-
producing foods
● Avoid carbonated drinks
Supplementation ● Replace lost calcium with
supplementation
● Supplement with lactinex
granules or alternate with a
probiotic for 2–4 weeks to
control the increasing gas and
discomfort, as well as from
possible pancreatic insufﬁciency
(in HCC) and change in gut ﬂora
M
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Table 4 (continued)
Management Recommendations for Diarrhea and Dyspepsia
Diarrhea1,31–36 Dyspepsia22,38
General Tumor-Speciﬁc General Tumor-Speciﬁc
● Probiotics will help to aid
digestion and restore normal
GI ﬂora
Treatment ● Antimotility agents (eg,
loperamide [Imodium A-D;
McNeil-PPC, Inc., Fort
Washington, PA]) are an
effective way to treat diarrhea,
rather than waiting to see if
dietary changes are effective
● Prior to treatment, patients
should have loperamide
on hand
● Intermittent loperamide
treatment (as needed, followed
by two tablets every 4 hours)
can normalize motility and
control diarrhea
● Take loperamide at a dose of
4 mg, followed by 2 mg every
4 hours or after each loose stool
● Loperamide should be taken at
the onset of diarrhea, with or
without food
● With worsening diarrhea, a
standing dose of loperamide,
titrated to 12 pills/day is
reasonable
● Loperamide (2 mg) may be
taken prophylactically 30
minutes before the scheduled
sorafenib dose in patients who
● If dietary changes and
supplementation are ineffective,
follow with a proton pump
inhibitor (bid: 2 hours before or
after sorafenib dosing), on
which the patient can remain
for the duration of their
sorafenib therapy
● Sucralfate (Carafate; Aptalis
Pharma US, Bridgewater, NJ )
suspension, an antiulcer
medication, taken qd, may also
be helpful
A
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Table 4 (continued)
Management Recommendations for Diarrhea and Dyspepsia
Diarrhea1,31–36 Dyspepsia22,38
General Tumor-Speciﬁc General Tumor-Speciﬁc
experienced diarrhea with
previous sorafenib doses
● If loperamide is ineffective,
diphenoxylate/atropine is
recommended in a similar dose-
escalation fashion as loperamide
Other
medications
● For refractory diarrhea, opiates
(eg, codeine) may be used for
their antimotility effect on the
GI tract
● Cholestyramine (Questran; PAR
Pharmaceutical, Spring Valley,
NY), 4 g/tid, which binds bile
acids, may be helpful in treating
diarrhea in some patients;
however, it should be taken
separately from other
medications to avoid interaction
Cholestyramine ● HCC and RCC: Avoid NSAIDS
and aspirin
● DTC: cholestyramine is
contraindicated as it negatively
impacts synthroid/
levothyroxine replacement. If
used, take at night to minimize
drug interactions
● Cholestyramine is also
contraindicated in patients with
complete biliary obstruction
Sorafenib dose
reductions
● Sorafenib dose reduction (to
400 mg qd or every other day)
or interruption may be necessary
for unmanageable or grade 3 or
4 diarrhea until diarrhea returns
to baseline or grade 1
Abbreviations: bid, twice a day; DTC, radioactive iodine-refractory differentiated thyroid cancer; GI, gastrointestinal; HCC, hepatocellular carcinoma; NSAID, nonsteroidal anti-
inﬂammatory; qd, once per day; RCC, renal cell carcinoma; tid, three times a day.
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A clinician’s perspective S11with HCC2 and RCC6 (see Tables 1 and 2); however,
this may be the product of longer treatment duration
in patients with DTC. Also, it should be noted that
data for DTC are phase II, while data from the HCC
and RCC trials are phase III and thus more mature.
Recent data from a retrospective cohort study of 101
patients with advanced solid tumors who wereTable 5. Recommendations for the Management o
Fatigue42
Parameter General
Dose reductions ● Dose reductions not needed
Adjust daily
schedules and
sorafenib dose
timing
● Adjust daily schedules according
until the fatigue passes
● Taking sorafenib in the evening
than during the day) may minim
daytime fatigue
Stimulants ● Stimulants are not recommende
however, patients can incorpora
caffeine into their diet
Screen for
depression
● Patients with long-term fatigue
also be screened for depression
Exercise may be
helpful
● For patients that are well enoug
exercise (eg, walking) may help
fatigue
● Weight-bearing exercise may als
replace lost skeletal muscle mas
which may be lost following
prolonged GI distress. This tend
concomitantly lift fatigue, depre
and, often, diarrhea
Monitor
electrolytes and
hemoglobin
● Ensure electrolytes and hemoglo
are at normal levels, monitor at
visit; electrolyte imbalance from
diarrhea/nonhydration may cau
depression
● Monitor for hypophosphatemia
which worsens fatigue
● Monitor hemoglobin levels
● Monitor TSH levels every quarte
sorafenib has resulted in
hypothyroidism and subclinical
hypothyroidism. For clinical
hypothyroidism, treat with thyro
replacement medication
Control
encephalopathy
Abbreviations: GI, gastrointestinal; HCC, hepatocellular carcinoma; Ttreated with sorafenib (400 mg twice daily for ≥12
weeks) in a randomized discontinuation trial showed
that an increase in systolic blood pressure (SBP) as
well as the mean amplitude of change were signifi-
cantly greater in RCC patients than in non-
RCC patients.43 In this study, 72% and 32% of RCC
and non-RCC patients, respectively, developed anf Fatigue
(author experience)
Tumor-Speciﬁc
ly,
(rather
ize
d;
te
should
h,
with
o help
s,
s to
ssion
● HCC: patients are often not well
enough to exercise strenuously but
should be encouraged to do some
mild exercise daily
bin
every
se
,
r:
id
● HCC: control encephalopathy, which
may also impact fatigue
SH, thyroid-stimulating hormone.
M.S. Brose et alS12increase in SBP of at least 20 mm Hg (mean increase:
30 mm Hg [RCC] v 19 mmHg [non-RCC]); Po.003.
HTN usually occurs in the first 6 weeks of treatment
with sorafenib1; therefore, blood pressure (BP) should
be monitored regularly (at least once a week) at the
start of sorafenib therapy. Although some patients are
hypertensive before treatment with sorafenib and may
already be taking antihypertensive medications,
patients with advanced cirrhosis (eg, in HCC) are
characteristically hypotensive as a result of peripheral
vasodilation, which occurs in approximately half of
hospitalized patients with cirrhosis and ascites.44,45
Therefore, it is possible that sorafenib may actually
help to normalize BP in some of these patients.
Diarrhea, which may lead to dehydration and hypo-
tension, can mask HTN, which may reappear when
diarrhea is corrected. Once HTN is well controlled, it
often does not need to be readdressed, and the dose of
sorafenib does not generally have to be adjusted.46Other Cardiovascular Risks
There are additional cardiovascular risks with the
long-term (41 year) use of sorafenib; these include
both thromboembolic and cardiac ischemic events.
The relative risk of tyrosine kinase inhibitor–associ-
ated arterial thromboembolic events (ATEs) appears
to differ by tumor type. In large clinical trials ofTable 6. Recommendations for the Management o
Management recomme
Parameter General
Hypertension ● Monitor blood pressure weekly d
the ﬁrst 6 weeks of sorafenib treat
● Education: all patients should che
their blood pressure a few times a
and report changes to their healt
team. “Healthy remembrance”: a
headache of 3 days’ duration can
HTN
● If patients have HTN before starti
sorafenib, bring under control wi
antihypertensive medication
● Patients are generally not refracto
antihypertensive treatment; there
there is usually no cause to discon
sorafenib treatment
Other
cardiovascular
risks
● May perform a stress test for som
patients with a cardiac history (b
at 6 months, and 1 year after sta
sorafenib therapy)
Abbreviations: DTC, radioactive iodine-refractory differentiated thyro
RCC, renal cell carcinoma.patients with HCC (N ¼ 297) and RCC (N ¼ 451), the
relative risk (95% confidence interval) of acquiring an
ATE compared with placebo was 2.03 (0.62–6.68)
and 6.00 (1.35–26.66), respectively. The difference
compared with control groups was significant in
patients with RCC (P ¼ .019) but not with HCC
(P ¼ .242).47 In a study of cardiac safety in patients
with RCC, a 2% incidence in left ventricular ejection
fraction decline was observed in patients with RCC.48
Management Approach. For HTN and all
cardiovascular AEs, patient education is extremely
important. Patients should be continually reminded
of cardiac adverse events and to report symptoms to
their healthcare team immediately. Treatment
recommendations may vary by tumor type (Table 6);
however, HTN should generally be managed
according to standard medical practice,1 following
guidelines by the Joint National Committee for the
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7).49
Portal HTN and Variceal Bleeding
Variceal bleeding, which is associated with portal
HTN, is HCC-specific and is not sorafenib-related.
Although uncommon, variceal bleeds can be signifi-
cant in patients with HCC and may be caused byf HTN and Other Cardiovascular Adverse Events
ndations1,22 (author experience)
Tumor-speciﬁc
uring
ment
ck
week
hcare
signal
ng
th
ry to
fore,
tinue
Antihypertensive medication
● HCC: use nonselective beta-blockers
(ie, carvedilol, nadolol, or propranolol),
followed by calcium channel blockers if
noneffective. There is an added beneﬁt
of decreased portal pressure in patients
with liver disease with use of
nonselective beta-blockers
● RCC: dihydropyridine calcium channel
blockers (eg, amlodipine) are
commonly used in the setting of RCC
● DTC: begin with a beta-blocker
e
efore,
rting
id cancer; HCC, hepatocellular carcinoma; HTN, hypertension;
A clinician’s perspective S13cirrhosis or hepatitis C infection in the presence of
cirrhosis. In patients with HCC enrolled in the phase
III SHARP (Sorafenib HCC Assessment Randomized
Protocol) trial, the risk of variceal bleeds was no
different between the sorafenib (2%) and placebo
(4%) groups.2 Overall, the risk for bleeding events in
all tumor types (including HCC, RCC, and DTC) has
been rare; therefore, it should not be a reason for
withholding sorafenib treatment or surgery
(Table 7). Routine variceal screening and prophy-
laxis as standard of care in patients with cirrhosis
should be employed.Wound Healing
Although the risk of poor wound healing is low
with sorafenib therapy, it still elicits concern among
clinicians. Fistula formation, which occurs ino1%
of patients with HCC and RCC1 can often appear at
the site of prior surgery and radiation. Primarily out
of concern for decreased perfusion leading to poorer
wound healing, recommendations are to stop sor-
afenib treatment 24 hours before surgery1 andTable 7. Recommendations for the Management
With HCC
Manageme
Parameter General
General ● The risk for bleeding events is low
therefore, it should never be a rea
for withholding therapy
Sorafenib
treatment
● Depending on the tumor type,
treatment should not be withheld
pending assessment for varices
● Complete variceal eradication prio
sorafenib treatment is not required
Portal
hypertension
management
● All patients with cirrhosis should b
screened for esophageal varices as
standard of care
● Nonselective beta-blockers (eg,
carvedilol, propranolol and nadolo
commonly used for primary proph
of variceal bleeding52
Education ● Patients should be reminded to re
vigilant and immediately report
symptoms to their healthcare team
1 year of treatment
Abbreviations: HCC, hepatocellular carcinoma; HTN, hypertension.restart once wound healing is well established. The
authors note that, contrary to recommendations in
the US prescribing information,1 they have not
stopped sorafenib therapy before surgery (eg, emer-
gency surgery) and have not observed any issues
with wound healing.Other AEs
Mucositis complications and oropharyngeal tox-
icities (usually grade 1 or grade 2) have been
observed in 30% to 40% of patients with RCC,6 as
well as in 47% of patients with DTC,10 and may
manifest as mouth ulcers, mouth sensitivities, and
lesions in the mouth. “Magic” mouthwash (lidocaine,
Maalox [Novartis Consumer Health, Parsippany, NJ]
plus sucralfate to reduce the sensitivity of the
mucosa) or salt water rinses may provide sympto-
matic relief. Data from a randomized, double-blind
clinical trial showed that 142 of 200 (71%) patients
with chemotherapy-induced mucositis obtained
relief (disappearance of signs and symptoms of
mucositis) within 12 days of treatment with theof Portal HTN and Variceal Bleeds in Patients
nt recommendations
Tumor-speciﬁc
;
son
● In cirrhosis, variceal bleeds do not seem
to correlate with platelet count50;
therefore, it is safe to continue with
sorafenib treatment
● HCC: sorafenib decreases portal
pressure51
r to
● In end-stage disease, the beneﬁts of
treatment may outweigh the risk of
withholding treatment
● For non–end-stage disease, a drug
holiday may be recommended
e
l) are
ylaxis
main
after
M.S. Brose et alS14use of either magic mouthwash; salt and sodium
bicarbonate; or chlorhexidine. However, differences
in efficacy between types of mouthwash were not
statistically significant.53 There also may be a con-
cern that the numbing effect from the lidocaine in
magic mouthwash may make swallowing difficult for
some patients.54CONCLUSIONS
Proactive and effective management of AEs that
may occur during treatment with sorafenib will
allow patients to remain on their prescribed dose,
thereby maximizing its therapeutic benefit. For
patients with RCC and HCC, in the absence of
cirrhosis or with Child-Pugh A cirrhosis and good
performance status, starting on a full sorafenib dose
is recommended.1 The starting dose under review in
patients with DTC is also 400 mg twice per day.
Physicians can help patients by reviewing poten-
tial AEs with them prior to beginning therapy,
emphasizing effective management strategies.
Patients should be encouraged to call their health-
care team between visits to quickly address issues of
toxicity. Overall, patient education and empower-
ment, both prior to and during sorafenib therapy, is
of primary importance in helping to prevent and
manage AEs, such as HFSR and diarrhea. Patients also
should be reminded to proactively monitor their BP
and, with long-term sorafenib use, remain aware of
and report cardiac symptoms without delay.
Through effective management of AEs that com-
monly occur during treatment with sorafenib,
patients may enjoy a better QOL and receive full
benefit of their sorafenib treatment.
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